Vaginal dryness and painful sex after menopause are usually part of the genitourinary syndrome of menopause. Lubricants and moisturizers help mild symptoms; low-dose vaginal estrogen and other prescription options treat moderate to severe symptoms.
Vaginal dryness, irritation and pain with sex after menopause are most often caused by falling estrogen, a condition now called the genitourinary syndrome of menopause (GSM). It is common, often underdiagnosed, and in most cases it can be managed effectively. Over-the-counter lubricants and moisturizers are enough for many women with mild symptoms, while low-dose vaginal estrogen and other prescription options treat moderate to severe symptoms. Because pain and dryness can affect desire and closeness, treating them is often an important part of restoring intimacy.
GSM is the newer name for a group of symptoms affecting the vulva, vagina and urinary tract that result from lower estrogen levels. Symptomatic vulvovaginal atrophy, the older term, is one part of it. The 2020 position statement of The North American Menopause Society (NAMS) describes GSM as affecting roughly 27% to 84% of postmenopausal women and notes that it can significantly impair health, sexual function and quality of life.
The FDA describes these as symptoms due to changes to the vagina, vulva and urinary tract caused by decreased estrogen. In everyday terms, that can mean dryness or irritation, discomfort with sex, or urinary symptoms. Our article on perimenopause and menopause hormone therapy options explains the broader hormonal changes.
The NAMS statement says the choice of therapy depends on symptom severity, the effectiveness and safety of treatments for the individual, and patient preference.
| Option | Prescription needed? | Best suited for |
|---|---|---|
| Vaginal lubricants (used during sex) | No | Mild dryness or discomfort during sex |
| Vaginal moisturizers (used regularly) | No | Mild, ongoing dryness |
| Low-dose vaginal estrogen | Yes | Moderate to severe GSM |
| Vaginal DHEA (prasterone) | Yes | Moderate to severe GSM |
| Ospemifene (oral) | Yes | Moderate to severe GSM |
| Systemic hormone therapy | Yes | GSM along with other symptoms such as hot flashes |
NAMS states that nonhormone therapies available without a prescription provide sufficient relief for most women with mild symptoms. ACOG also lists lubricants and vaginal moisturizers as helpful for dryness related to menopause. Lubricants are used during sexual activity, while moisturizers are used on a regular schedule to keep tissue more comfortable day to day. ACOG notes that some products, including perfumed soaps, douches and certain lubricants, can cause contact dermatitis, so if you notice irritation, it may be worth trying a different, fragrance-free product and mentioning it to your provider.
Low-dose vaginal estrogen acts locally on the tissue. NAMS lists it among the effective treatments for moderate to severe GSM and states that when low-dose vaginal estrogen is used, a progestogen is not indicated. It also notes that long-term studies of endometrial safety are lacking, with clinical trial data not extending beyond 1 year. Estradiol vaginal cream is one form of this treatment, and how often and how much to use is set by the prescriber.
Vaginal DHEA (prasterone) and oral ospemifene, an estrogen agonist and antagonist, are also effective for moderate to severe GSM according to NAMS. Systemic hormone therapy treats GSM as well and may make sense when a woman also has bothersome hot flashes or night sweats.
NAMS concluded that there are insufficient placebo-controlled trials of energy-based therapies, including vaginal laser, to draw conclusions about their effectiveness and safety or to make treatment recommendations.
For many years, low-dose vaginal estrogen products carried the same boxed warning as systemic hormone therapy, based on findings from the Women's Health Initiative. The FDA noted that it received questions about whether those warnings were warranted, particularly for local vaginal estrogen-only products.
In November 2025, the FDA requested labeling changes for all menopausal hormone therapies, including local vaginal products. The requested changes include removing language about cardiovascular disease, breast cancer and probable dementia from the boxed warning, and removing the recommendation to use the lowest effective dose for the shortest time. For local vaginal estrogen, the FDA also asked manufacturers to condense safety information and prioritize what is most relevant to the vaginal formulation.
The practical meaning is that the label is moving closer to what NAMS had already described: low-dose vaginal estrogen is an effective treatment whose risks should be weighed individually. It is still a prescription medication, and a licensed provider should review your history before prescribing it.
NAMS states that there are insufficient data to confirm the safety of vaginal estrogen, DHEA or ospemifene in women with breast cancer, and that care should consider the woman's needs and the recommendations of her oncologist.
ACOG notes that nearly 3 out of 4 women have pain during intercourse at some point in their lives, and menopause is only one possible cause. Others include skin conditions of the vulva, vulvodynia, vaginismus, infections and gynecologic conditions such as endometriosis or ovarian cysts. ACOG recommends seeing a health care professional for frequent or severe pain during sex so that these conditions can be ruled out.
Desire can also change for reasons beyond physical comfort, including stress, fatigue, relationship factors and medications. If low desire persists after physical symptoms are treated and it causes distress, the options differ by product. The flibanserin (Addyi) label, updated in December 2025, covers women under 65 with acquired, generalized hypoactive sexual desire disorder. The bremelanotide (Vyleesi) label states that it is not indicated for postmenopausal women, so use of PT-141 after menopause is off-label. Compounded PT-141 is not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Our article on low sexual desire in women covers evaluation in more detail.
No. NAMS describes GSM as likely underdiagnosed and undertreated, and it states that in most cases symptoms can be managed effectively. Raising it with a licensed provider is the first step.
No. Low-dose vaginal estrogen acts locally, and NAMS states that a progestogen is not indicated with it. Systemic hormone therapy affects the whole body and has a different benefit and risk profile.
No. They are available over the counter, and NAMS says they provide sufficient relief for most women with mild symptoms. If symptoms are moderate to severe, or do not improve, a licensed provider can discuss prescription options.
It can help when pain or discomfort is part of the problem. ACOG explains that problems with sexual response and pain are often connected. When low desire continues after physical symptoms improve, a separate evaluation is worthwhile.
Vaginal dryness and painful sex are common after menopause, and they are treatable. A licensed provider can examine the cause, explain the full range of options from over-the-counter products to prescription therapy, and help you choose what fits your health history. You can explore estradiol options or read more on our sexual health page. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
Low desire is common and only becomes a clinical concern when it causes distress. Evaluation looks at health, medications, hormones, mood and relationships first; FDA-approved medications exist for specific, diagnosed cases.
Read articleThe FDA warns that many sexual enhancement products sold as supplements, honeys, chocolates or "natural" pills contain hidden prescription drug ingredients that can cause dangerous drops in blood pressure and other harm.
Read articleMany common medications, including some antidepressants, blood pressure medicines, hormonal treatments and opioids, can affect desire, arousal, erections or orgasm. Never stop a medication on your own; talk with your prescriber about options.
Read article